Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with imiquimod in indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Teulings, Hansje-Eva, Tjin, Esther P. M., Willemsen, Karina J., van der Kleij, Stephanie, ter Meulen, Sylvia, Kemp, E. Helen, Krebbers, Gabrielle, van Noesel, Carel J. M., Franken, Cornelis L. M. C., Drijfhout, Jan W., Melief, Cornelis J. M., Nieuweboer-Krobotova, Ludmila, Nieweg, Omgo E., van der Hage, Jos A., van der Veen, J. P. Wietze, Relyveld, Germaine N., Luiten, Rosalie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889200/
https://www.ncbi.nlm.nih.gov/pubmed/29632737
http://dx.doi.org/10.1080/2162402X.2017.1419113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889200/
https://www.ncbi.nlm.nih.gov/pubmed/29632737
http://dx.doi.org/10.1080/2162402X.2017.1419113

Ejemplares similares